Stockscreener 앱 받기
19.13
0.80%
-0.14
시간 외 거래:
18.23
-0.90
-4.70%
Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Travere Therapeutics Expands Team with 77,200 Shares in Strategic Equity Grants - StockTitan
US Bancorp DE Has $554,000 Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Focal Segmental Glomerulosclerosis Treatment Market Size - openPR
Why Travere Therapeutics Inc. (TVTX) Went Up On Tuesday? - MSN
What To Expect From Travere Therapeutics Inc (TVTX) Q4 2024 Earnings - GuruFocus.com
Travere Therapeutics: Tricky Outlook Gives Me Pause For ThoughtDowngrade - Seeking Alpha
When the Price of (TVTX) Talks, People Listen - Stock Traders Daily
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $44.00 - Defense World
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat
20,749 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Purchased by Ieq Capital LLC - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $35.00 at Citigroup - MarketBeat
Wedbush Lowers Earnings Estimates for Travere Therapeutics - Defense World
Can Ligand's Triple FDA Wins Offset Its $31M Q4 Loss? Revenue Jumps 52% - StockTitan
Q1 EPS Estimate for Travere Therapeutics Lowered by Analyst - MarketBeat
Impax Asset Management Group plc Purchases New Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Travere Therapeutics' (TVTX) Overweight Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Analyst Expectations For Travere Therapeutics's Future - Benzinga
Travere Therapeutics to Participate at Upcoming Investor Conferences - The Manila Times
Citi raises Travere Therapeutics price target to $35, maintains buy By Investing.com - Investing.com Canada
Citi raises Travere Therapeutics price target to $35, maintains buy - Investing.com India
Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease Drug - MSN
Travere Therapeutics, Inc. (TVTX): the Best Performing Pharma Stock So Far in 2025 - Insider Monkey
Travere Therapeutics price target raised to $30 from $24 at TD Cowen - Yahoo Finance
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2024 Earnings Call Transcript - Insider Monkey
Travere Therapeutics Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Travere Therapeutics (NASDAQ:TVTX) Shares Gap Down Following Weak Earnings - Defense World
Travere Therapeutics’ Earnings Call Reveals Growth and Challenges - TipRanks
US FDA approves Mirum Pharma's genetic disorder drug -February 21, 2025 at 12:07 pm EST - Marketscreener.com
Travere Therapeutics, Inc. SEC 10-K Report - TradingView
Travere therapeutics chief medical officer sells $60k in stock - MSN
Travere Therapeutics Inc (TVTX) Q4 2024 Earnings Call Highlights: Strong Phil Spari Sales and ... - Yahoo Finance
Travere Therapeutics Inc (TVTX) Q4 2024 Earnings Call Highlights: Strong Phil Spari Sales and ... By GuruFocus - Investing.com Canada
Travere Therapeutics Posts Strong 2024 Financial Results - TipRanks
Earnings call transcript: Travere Therapeutics Q4 2024 sees earnings beat but stock drops - Investing.com
Compared to Estimates, Travere (TVTX) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Travere: Q4 Earnings Snapshot - San Antonio Express-News
Travere: Q4 Earnings Snapshot -February 20, 2025 at 04:27 pm EST - Marketscreener.com
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - MSN
Entropy Technologies LP Makes New $214,000 Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
TVTX Stock Soars to 52-Week High, Reaching $20.36 - MSN
Curious about Travere (TVTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance
Travere Therapeutics (TVTX) Projected to Post Earnings on Thursday - MarketBeat
Leerink Partnrs Has Strong Forecast for TVTX FY2026 Earnings - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Given New $45.00 Price Target at Evercore ISI - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Peter Heerma Sells 3,074 Shares - MarketBeat
Travere therapeutics director Roy Baynes sells $220,000 in stock - MSN
Sandra Calvin Sells 54,244 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock - MarketBeat
0.49%
1.87%
자본화:
|
볼륨(24시간):